MedTrace Logo

Phenylephrine Pediatric Pharmacokinetic Study

NCT00762567 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2011-10-06

No results posted yet for this study

Summary

To characterize the pharmacokinetics of phenylephrine in two pediatric populations: children, ages 2 to \<12 years, and adolescents, ages 12 to \<18 years.

Conditions

  • Rhinitis

Interventions

DRUG

phenylephrine HCl

A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule

Sponsors & Collaborators

  • Johnson & Johnson Consumer and Personal Products Worldwide

    lead INDUSTRY

Principal Investigators

  • Dolly Parasrampuria, PhD · McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00762567 on ClinicalTrials.gov